PROKIDNEY CORP. (PROK) earnings date
Mar 19, 2027, after close estimated
Estimated from the company's SEC filing cadence. The company has not confirmed it. Companies usually announce two to four weeks ahead.
- Fiscal period
- Q4 FY2026
- Confidence
- 40% chance of landing within a day
- Source
- Filing history on EDGAR
- Last checked
- 2026-11-19
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
How this company behaves
| Announces its report date | Not enough announcements on file yet to say |
| Reports after the quarter ends | 43 days, typically, give or take 16 (last 8 releases) |
Last 8 releases
| Period | Released | Timing | Days after period end | Filing |
|---|---|---|---|---|
| Q3 FY2026 | Thu, Nov 12, 2026 | after close | 43 | 8-K |
| Q2 FY2026 | Mon, Aug 10, 2026 | after close | 41 | 8-K |
| Q1 FY2026 | Fri, May 15, 2026 | during market hours | 45 | 8-K |
| Q4 FY2025 | Wed, Mar 18, 2026 | after close | 77 | 8-K |
| Q3 FY2025 | Mon, Nov 10, 2025 | after close | 41 | 8-K |
| Q2 FY2025 | Tue, Aug 12, 2025 | after close | 43 | 8-K |
| Q1 FY2025 | Mon, May 12, 2025 | after close | 42 | 8-K |
| Q4 FY2024 | Mon, Mar 17, 2025 | after close | 76 | 8-K |
What they guided beta
| Q3 FY2026 | "On track to deliver pivotal Phase 3 PROACT 1 surrogate endpoint (eGFR slope) topline results in Q2 2027" exhibit |
| Q3 FY2026 | "Anticipate completing full enrollment for the PROACT 1 confirmatory analysis in Q1 2027 with over 500 patients, up from 470, driven by accelerated patient recruitment in mid-2026" exhibit |
| Q3 FY2026 | "On track to deliver pivotal Phase 3 PROACT 1 surrogate endpoint (eGFR slope) topline results in Q2 2027; the efficacy analysis set is expected to include approximately 320 patients" exhibit |
| Q3 FY2026 | "Anticipate completing full enrollment for the PROACT 1 confirmatory analysis in Q1 2027 with over 500 patients, up from 470, driven by an acceleration in patient recruitment in mid-2026; the confirmatory endpoint (composite time-to-event) topline readout is expected in 2H 2029 American Society of Nephrology (ASN) Kidney Week 2026" exhibit |
| Q3 FY2026 | "Rilparencel: Potential to Offer Meaningful Time NOVEL autologous cell therapy made from a patient’s own kidney cells CLINICAL DATA shows kidney function stabilization in multiple Phase 2 studies WELL-TOLERATED outpatient procedure; no preconditioning or immunosuppression PHASE 3 STUDY is ongoing with pivotal topline results expected in Q2 2027 For Patients" exhibit |
| Q3 FY2026 | "Anticipate enrolling over 500 patients (up from 470) driven by an acceleration in patient recruitment in mid-2026." exhibit |
| Q3 FY2026 | "Day –93 to Day 0 ScreeningVisit Sham Cohort Sham 1st Rilparencel Injection Sham 2nd Rilparencel Injection Sham Biopsy End of Study (EOS) 1st Rilparencel Injection 2nd Rilparencel Injection Biopsy End of Study (EOS) PHASE 3 REGEN-006 (PROACT 1)Rilparencel Phase 3 Registrational Study Design Topline results for the eGFR slope surrogate endpoint anticipated in Q2 2027 Key Entry Criteria Confirmatory Composite Time-to-Event Endpoint Type 2 diabetes and CKD 30-80 years of age eGFR ≥20 and ≤35 mL/min/1.73m2 UACR 300-5,000 mg/g for eGFR 30-35 HbA1c <9.5% 3 months 3 months 3 months 3 months R 1:1 " exhibit |
| Q3 FY2026 | "KEY MILESTONES CORPORATE HIGHLIGHTS Clean Balance Sheet and Clear Path to Value Creation Shares Outstanding 302,381,712* Cash Position $142M** Cash Runway Expected to fund operations into mid-2027 Analyst Coverage 7 Firms 1H 2029 Q1 2027 Q2 2027 Complete full enrollment for the Phase 3 PROACT 1 study Phase 3 PROACT 1 topline data readout of surrogate endpoint (eGFR slope) Potential accelerated approval and commercial launch of rilparencel *Class A and Class B as of November 6, 2026 **Cash, cash equivalents and marketable securities as of September 30, 2026" exhibit |
Get this as JSON
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/next/PROK
# how far back the record goes for this company
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/coverage/PROK
Put this date on your page
A badge that stays current. It links back to this page and needs no key. Embed it unmodified, with its link to this page intact: the badge is too small to carry the notice below, so the page it links to does.
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
HTML
<a href="https://veritasdata.dev/company/PROK/"><img src="https://veritasdata.dev/embed/PROK.svg" alt="PROK earnings date" width="240" height="56"></a>
Markdown
[](https://veritasdata.dev/company/PROK/)
Script
<script async src="https://veritasdata.dev/embed/PROK.js"></script>
Get a free key: 100 calls, every company
Sign in with GitHub or Google. The key works on every endpoint and in the MCP server.
curl -H "X-API-Key: vt_live_..." "https://api.veritasdata.dev/v1/next/PROK"
Dates come only from SEC EDGAR and company announcements. Nothing here is investment advice.